MA35336B1 - Bloqueurs des canaux sodiques voltage-dependants - Google Patents

Bloqueurs des canaux sodiques voltage-dependants

Info

Publication number
MA35336B1
MA35336B1 MA36731A MA36731A MA35336B1 MA 35336 B1 MA35336 B1 MA 35336B1 MA 36731 A MA36731 A MA 36731A MA 36731 A MA36731 A MA 36731A MA 35336 B1 MA35336 B1 MA 35336B1
Authority
MA
Morocco
Prior art keywords
voltage
respiratory diseases
sodium channel
channel blockers
dependent sodium
Prior art date
Application number
MA36731A
Other languages
English (en)
Inventor
Jeffrey Charles Boehm
Roderick S Davis
Jeffrey Kerns
Guoliang Lin
Robert D Murdoch
Hong Nie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47437403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35336(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA35336B1 publication Critical patent/MA35336B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne, en général, l'utilisation de composés bloqueurs des canaux sodiques voltage-dépendants qui comprennent des précurseurs, des intermédiaires, des monomères et des dimères correspondants; des compositions pharmaceutiques correspondantes; la préparation des composés; et des méthodes de traitement des maladies respiratoires et des maladies des voies respiratoires. L'invention concerne également en particulier des méthodes et des utilisations permettant de traiter des maladies respiratoires et des maladies des voies respiratoires, qui consistent à administrer une quantité efficace du composé de l'invention à un sujet le nécessitant.
MA36731A 2011-07-06 2014-02-05 Bloqueurs des canaux sodiques voltage-dependants MA35336B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505075P 2011-07-06 2011-07-06
PCT/US2012/045350 WO2013006596A1 (fr) 2011-07-06 2012-07-03 Bloqueurs des canaux sodiques voltage-dépendants

Publications (1)

Publication Number Publication Date
MA35336B1 true MA35336B1 (fr) 2014-08-01

Family

ID=47437403

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36731A MA35336B1 (fr) 2011-07-06 2014-02-05 Bloqueurs des canaux sodiques voltage-dependants

Country Status (21)

Country Link
US (1) US20140121213A1 (fr)
EP (1) EP2729149A4 (fr)
JP (1) JP2014518281A (fr)
KR (1) KR20140059774A (fr)
CN (1) CN103764148A (fr)
AR (1) AR087053A1 (fr)
AU (1) AU2012279091A1 (fr)
BR (1) BR112014000259A2 (fr)
CA (1) CA2840394A1 (fr)
CL (1) CL2014000020A1 (fr)
CO (1) CO6821963A2 (fr)
CR (1) CR20140002A (fr)
DO (1) DOP2014000001A (fr)
EA (1) EA201490210A1 (fr)
MA (1) MA35336B1 (fr)
MX (1) MX2014000112A (fr)
PE (1) PE20141385A1 (fr)
PH (1) PH12014500006A1 (fr)
TW (1) TW201302707A (fr)
WO (1) WO2013006596A1 (fr)
ZA (1) ZA201309533B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122897A1 (fr) 2012-02-13 2013-08-22 Amgen Inc. Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
ES2663798T3 (es) 2013-03-14 2018-04-17 Daiichi Sankyo Company, Limited Fármaco para enfermedades respiratorias
US10668067B2 (en) 2016-07-20 2020-06-02 Amgen Inc. Pyridine sulfonamides
CN113227077B (zh) * 2018-12-13 2024-10-29 英特维特国际股份有限公司 一种制备1-[(3r,4s)-4-氰基四氢吡喃-3-基]-3-[(2-氟-6-甲氧基-4-吡啶基)氨基]吡唑-4-甲酰胺的方法
CN109796402A (zh) * 2018-12-28 2019-05-24 京博农化科技有限公司 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147864A2 (fr) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Procédés d'utilisaton de composés pipérazine dans le traitement de maladies ou états médiés par le canal sodium
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers

Also Published As

Publication number Publication date
EP2729149A1 (fr) 2014-05-14
EP2729149A4 (fr) 2015-01-07
CN103764148A (zh) 2014-04-30
ZA201309533B (en) 2014-08-27
KR20140059774A (ko) 2014-05-16
US20140121213A1 (en) 2014-05-01
MX2014000112A (es) 2014-01-31
EA201490210A1 (ru) 2014-05-30
TW201302707A (zh) 2013-01-16
CR20140002A (es) 2014-03-05
BR112014000259A2 (pt) 2017-02-14
CO6821963A2 (es) 2013-12-31
PH12014500006A1 (en) 2014-02-10
DOP2014000001A (es) 2014-04-30
CL2014000020A1 (es) 2014-08-01
JP2014518281A (ja) 2014-07-28
WO2013006596A1 (fr) 2013-01-10
CA2840394A1 (fr) 2013-01-10
PE20141385A1 (es) 2014-10-29
AU2012279091A1 (en) 2014-01-16
AR087053A1 (es) 2014-02-12

Similar Documents

Publication Publication Date Title
MA35836B1 (fr) 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA38959A1 (fr) Modulateurs du facteur b du complément
EA201290919A1 (ru) Индазольные соединения и их применение
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
EA201290644A1 (ru) Блокаторы натриевых потенциал-зависимых каналов
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
EA201170473A1 (ru) Морфинановые соединения
GEP20166438B (en) Imidazopyrrolidinone compounds
MA32981B1 (fr) Regime posologique pour un agoniste du recepteur s1p
MA39193B1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA200970706A1 (ru) Новые фармацевтические композиции
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
EA200970512A1 (ru) Лечение по поводу множественной миеломы
EA201201541A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MX391620B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата